Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score
Liver International · 2024
DOI: 10.1111/liv.15916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Alessio Gerussi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), IRCCS Fond…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Genetic Predisposition to Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AMAF Monza Onlus, AIRCS.
Abstract (Originalsprache)
Background and Aims Genetic variants influence primary biliary cholangitis (PBC) risk. We established and tested an accurate polygenic risk score (PRS) using these variants.
Methods
Data from two Italian cohorts (OldIT 444 cases, 901 controls; NewIT 255 cases, 579 controls) were analysed. The latest international genome‐wide meta‐analysis provided effect size estimates. The PRS, together with human leukocyte antigen ( HLA ) status and sex, was included in an integrated risk model.
Results
Starting from 46 non‐ HLA genes, 22 variants were selected. PBC patients in the OldIT cohort showed a higher risk score than controls: −.014 (interquartile range, IQR, −.023, .005) versus −.022 (IQR −.030, −.013) ( p < 2.2 × 10 −16 ). For genetic‐based prediction, the area under the curve (AUC) was .72; adding sex increased the AUC to .82. Validation in the NewIT cohort confirmed the model's accuracy (.71 without sex, .81 with sex). Individuals in the top group, representing the highest 25%, had a PBC risk approximately 14 times higher than that of the reference group (lowest 25%; p < 10 −6 ).
Conclusion
The combination of sex and a novel PRS accurately discriminated between PBC cases and controls. The model identified a subset of individuals at increased risk of PBC who might benefit from tailored monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy.
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- IRCCS Humanitas Research Hospital, Milan, Italy.
- Bicocca Bioinformatics Biostatistics and Bioimaging Centre-B4, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
ORCID-Profile: Marco Carbone, Pietro Invernizzi
Förderung
- AMAF Monza Onlus
- AIRCS
Zitieren
APA
Gerussi, A., Cappadona, C., Bernasconi, D. P., Cristoferi, L., Valsecchi, M. G., Carbone, M., Invernizzi, P., Asselta, R., & Italian PBC Genetic Study Group (2024). Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score. Liver International. https://doi.org/10.1111/liv.15916
Vancouver
Gerussi A, Cappadona C, Bernasconi DP, Cristoferi L, Valsecchi MG, Carbone M, et al. Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score. Liver International. 2024. doi:10.1111/liv.15916
BibTeX
@article{Gerussi2024,
author = {Gerussi, Alessio and Cappadona, Claudio and Bernasconi, Davide Paolo and Cristoferi, Laura and Valsecchi, Maria Grazia and Carbone, Marco and Invernizzi, Pietro and Asselta, Rosanna and Italian PBC Genetic Study Group, Italian PBC Genetic Study Group},
title = {Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15916}
}
EUVIMED